BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33478201)

  • 1. Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances.
    Chen Z; Cui N; Zhao JS; Wu JF; Ma F; Li C; Liu XY
    Eur J Histochem; 2021 Jan; 65(1):. PubMed ID: 33478201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and significance of CMTM5 and epidermal growth factor receptor in prostate cancer].
    Yuan YQ; Zhang YX; Liu ZH; Qin CP; Sheng ZZ; Xu T; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Aug; 47(4):571-6. PubMed ID: 26284387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.
    Li L; Hu Y; Chen D; Zhu J; Bao W; Xu X; Chen H; Chen W; Feng R
    Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34791506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer.
    Xu C; Liu F; Xiang G; Cao L; Wang S; Liu J; Meng Q; Xu D; Lv S; Jiao J; Niu Y
    J Exp Clin Cancer Res; 2019 Jun; 38(1):238. PubMed ID: 31171012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer.
    Li P; Liu K; Li L; Yang M; Gao W; Feng J; Lv Y; Qu X; Kong B
    Int J Gynecol Cancer; 2011 Oct; 21(7):1248-55. PubMed ID: 21841490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma.
    Zhang H; Nan X; Li X; Chen Y; Zhang J; Sun L; Han W; Li T
    Biochem Biophys Res Commun; 2014 May; 447(2):304-10. PubMed ID: 24721428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research advances in CKLF-like MARVEL transmembrane domain containing member 5].
    Yuan YQ; Xiao YB; Liu ZH; Zhang XW; Xu T; Wang XF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Dec; 34(6):625-8. PubMed ID: 23286412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CMTM5 inhibits the tumor cell behavior of prostate cancer by downregulation of HER2].
    Xu T; Li J; Xiao YB; Liu ZH; Li Q; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 42(4):386-90. PubMed ID: 20721248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Abnormally lower expression of cmtm5 gene in bone marrow cells from patients with multiple myeloma].
    Niu JH; Bao L; Zhang Y; Li JL; Li LD; Xie M; Qin YZ; Lai YY; Jiang Q; Shi HL; Liu YR; Jiang B; Chen SS; Huang XJ; Ruan GR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):363-7. PubMed ID: 20416169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
    Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
    Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of miR-10b-3p promotes the progression of hepatocellular carcinoma cells via targeting CMTM5.
    Guan L; Ji D; Liang N; Li S; Sun B
    J Cell Mol Med; 2018 Jul; 22(7):3434-3441. PubMed ID: 29691981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo.
    Xiao Y; Yuan Y; Zhang Y; Li J; Liu Z; Zhang X; Sheng Z; Xu T; Wang X
    Clin Transl Oncol; 2015 Jun; 17(6):431-7. PubMed ID: 25387568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMTM5/7 are biomarkers and prognostic factors in human breast carcinoma.
    Wu J
    Cancer Biomark; 2020; 29(1):89-99. PubMed ID: 32568178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
    Esheba GE; Hassan AA
    J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent inactivation of MCC/CTNNBIP1 and overexpression of phospho-beta-catenin(Y654) are associated with breast carcinoma: Clinical and prognostic significance.
    Mukherjee N; Dasgupta H; Bhattacharya R; Pal D; Roy R; Islam S; Alam N; Biswas J; Roy A; Roychoudhury S; Panda CK
    Biochim Biophys Acta; 2016 Sep; 1862(9):1472-84. PubMed ID: 27208794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibitory effect of CMTM5 on xenografted human prostatic cancer in nude mice].
    Xiao YB; Xie J; Zhang GX; Li J; Hao YC; Zhang XW; Liu ZH; Xu T; Wang XF
    Zhonghua Nan Ke Xue; 2012 Mar; 18(3):195-9. PubMed ID: 22474980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of aspirin response-related transcripts in patients with coronary artery disease and preliminary investigation on CMTM5 function.
    Zhang JW; Liu TF; Chen XH; Liang WY; Feng XR; Wang L; Fu SW; McCaffrey TA; Liu ML
    Gene; 2017 Aug; 624():56-65. PubMed ID: 28457985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akt1 inhibition promotes breast cancer metastasis through EGFR-mediated β-catenin nuclear accumulation.
    Li W; Hou JZ; Niu J; Xi ZQ; Ma C; Sun H; Wang CJ; Fang D; Li Q; Xie SQ
    Cell Commun Signal; 2018 Nov; 16(1):82. PubMed ID: 30445978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of cyclin D1, β-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast.
    Cheng CW; Liu YF; Yu JC; Wang HW; Ding SL; Hsiung CN; Hsu HM; Shieh JC; Wu PE; Shen CY
    Ann Surg Oncol; 2012 Dec; 19(13):4129-39. PubMed ID: 22864797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between expression of LRP16, Ki67 and EGFR and breast cancer clinical pathologic factors and prognosis.
    Yao DJ; Qiao S; Zhang Y; Zhao YT; Yuan CH
    Eur Rev Med Pharmacol Sci; 2017 Jul; 21(3 Suppl):47-51. PubMed ID: 28745792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.